Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
More loons are filling Maine's lakes with their ghostlike calls - 22026 Golden Globes live updates: Red carpet arrivals will kick off the night; Nikki Glaser set to host
- 3Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- 4Experience Is standing by: 10 Pleasant Setting up camp Areas to
- 5Audits of Espresso Types: Which Mix Is for You?
- 5 Language Learning Applications
- Commonsense Ways to work on Your Funds with a Restricted Pay
- A Manual for SUVs with Less Noteworthy Gas Mileage
- Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
- Sentimental tree to shine at Arctic League annual broadcast
- Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure
- Vote In favor of Your #1 sort of film
- Kendall Jenner addresses long-standing rumor about her sexuality
